White matter strokes (WMS) constitute 30% of all stroke subtypes yet there are limited animal models, preclinical trials and clinical trials. To date, there are no established studies of cell transplant in white matter repair nor are there existing therapies that facilitate brain recovery. White matter infarcts, in contrast to large artery strokes, primarily damage astrocytes, axons, oligodendrocytes and myelin. One proposed therapy is to transplant glial progenitor cells during the subacute period of white matter stroke in an attempt to regenerate brain tissue and alleviate neurological symptoms. One potential therapeutic cell line which biases cells towards an immature astrocytic fate, named human induced pluripotent stem cells- glial enriched progenitor cells (hiPSC-GEPs), has been developed by the Lowry lab at UCLA. This cell line was created with experimental manipulation of hiPSCs; oxygen tension and HIF activity were altered via brief exposure to a prolyl hydroxylase inhibitor (such as deferoxamine). hiPSC-GEPs injected into white matter lesions are hypothesized to migrate diffusely and mature into astrocytes; this would ultimately induce endogenous oligodendrocyte precursors to proliferate, activate remylenation of axons and stimulate cortical connection regeneration. Motor deficits were assessed using grid-walking and cylinder tasks. Axonal sprouting was evaluated by analysis of axonal labeling in coronal tissue sections using fluorescent measurement methods.